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• we performed the first meta-analysis to examine the effect of metformin on 
mortality in endometrial cancer. 
• Metformin use is associated with a significant reduction in overall mortality. 
• The findings suggest that good glycemic control may improve survival in 
endometrial cancer. 





Systematic review and meta-analysis of the effect of metformin treatment 
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Background: Obesity, insulin resistance and type 2 diabetes mellitus (T2DM) have been 
associated with endometrial cancer (EC). In this systematic review and meta-analysis we 
evaluated the effect of metformin on clinical outcomes in patients with EC and insulin 
resistance or T2DM. 
Methods: Four research databases were searched for original articles published in all 
languages up to 30
 
October 2016. Outcomes of interest were overall mortality (OM), 
cancer-specific mortality, disease progression, and metastases. We performed a random 
effect meta-analysis of adjusted effects expressed as hazard ratios (HR); heterogeneity 
among studies was described with the I
2
 statistic. 
Results: Of the 290 retrieved citations, 6 retrospective cohort studies in women with EC 
(n=4,723) met the inclusion criteria, and 8.9% to 23.8% were treated with metformin; OM 
data was available from 5 studies. In 4 studies of EC patients (n=4,132), metformin use was 
associated with a significant reduction in OM in comparison with not using metformin 
(adjusted HR [aHR] 0.64, 95% CI 0.45-0.89, p=0.009). In three studies evaluating patients 
with EC and T2DM (n=2,637), metformin use was associated with a significant reduction 
in OM (aHR 0.50, 95%CI 0.34-0.74, p=0.0006). There was low to moderate heterogeneity 
of adjusted effects across studies. There was no information about the effect of metformin 
on cancer-specific mortality, disease progression, or metastases. 
Conclusions: Metformin treatment is associated with a significant reduction in OM 
irrespective of diabetes status in patients with EC. The survival benefit suggests that 
diabetes screening and maintenance of good glycemic control may improve outcomes in 
EC. 
Keywords: Endometrial cancer; Metformin; Type 2 diabetes mellitus; Overall mortality. 













1. Introduction  
Endometrial cancer (EC) is the most common female malignant genital neoplasia in 
developed countries, and the fourth most common female malignancy overall. It is 
considered a hormone-dependent cancer, and peak incidence is in women between 50 and 
70 years. During the menstrual cycle, estrogen has been postulated to create a pro-
carcinogenic environment during the menstrual cycle; pregnancies interrupt such 
endometrial stimulus.
1
 Obese postmenopausal women with endometrioid EC have higher 
levels of estrogens and related metabolites, increased prevalence of type 2 diabetes mellitus 
(T2DM) and hyperinsulinemia than women without EC.
2-4
 Excessive body weight may 
contribute to the development of EC since fatty tissue produces large amounts of estrogen. 
In addition, obesity, T2DM, hyperinsulinemia and insulin resistance have been associated 
with endometrial carcinogenesis and increased mortality.
2,4-11
 
The biguanide metformin is the first-line treatment for individuals with T2DM. Metformin 
is known to modulate molecular pathways implicated in several cancers and because of 
these antitumor properties, metformin may have a role in cancer prevention and 
treatment.
12,13
In subjects with T2DM, metformin treatment is associated with reduced risk 
for cancer development in observational studies, although this finding has not been 
supported by randomized controlled trials.
8
 In patients with EC, short-term preoperative 
metformin therapy significantly reduces DNA synthesis, insulin, glucose, insulin-growth 
factor 1 (IGF-1) and other insulin resistance-related markers.
14,15
Although, metformin as a 
cancer therapeutic has generated great interest, metformin effects on stabilizing metabolic 
status and thereby reducing EC mortality remains controversial.
8,16,17
 
The possibility of prevention of EC recurrence after primary treatment is crucial in long-
term patient management. The aim of the current systematic review and meta-analysis was 













to determine the effect of metformin treatment on overall mortality, cancer-specific 




2.1. Data sources and searches 
A comprehensive literature search was performed using PubMed-Medline, Embase, Web 
of Science and Scopus from database inception through 30
th
 October 2016. Database 
searches were performed independently by two authors (VP and FRPL). The PubMed 
search strategy is available in the Supplement. 
The following pre-determined inclusion criteria were used: (i) cohort studies evaluating the 
effect of metformin treatment in women with EC, (ii) study population of patients ≥18 
years, and (iii) study in any language. Our exclusion criteria were: (i) no control group and 
(ii) data for metformin use and outcomes of interest were not available or could not be 
extracted for each of the metformin and non-metformin groups. 
 
2.2. Study selection, data extraction, and risk of bias assessment 
A list of retrieved articles was reviewed independently by two sets of investigators 
(Zaragoza and Lima) to choose potentially relevant articles, and disagreements on 
inclusion/exclusion were discussed and resolved by consensus. Two sets of reviewers 
(Zaragoza and Lima) independently extracted data from included studies. The following 
information was extracted: mean age, body mass index, EC histology, and endometrial 
cancer-related outcomes (duration of follow up, overall mortality, cancer-specific 
mortality, disease progression, metastases), whenever available. Both unadjusted and 
adjusted effects evaluating the association between metformin vs non-metformin and the 













clinical outcomes and expressed as hazard ratios (HR) were extracted per study. Also, the 
variables used to adjust the effects were extracted. One author (VP) reviewed the 
extractions for inconsistencies, and two authors (VP, FRPL) reached consensus.  
The Newcastle Ottawa Scale (NOS) for cohort studies was used to evaluate risk of bias;
18
 
this assessment was done independently by two investigators (VP, FRPL). The NOS 
evaluates nine items of selection of exposure and non-exposure groups, comparability of 
exposure and non-exposure groups, and outcome evaluation with a maximum number of 9 
stars (i.e. one per item). A total of 7 or more stars implies that the study has low risk of 
bias. 
 
2.3. Data analysis 
Our systematic review and meta-analysis follow the recommendations of the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
19
 As we 
expected some degree of heterogeneity across studies, the DerSimonian and Laird random 
effects models and inverse variance method were used for all meta-analyses.
20
 Associations 
between metformin use and dichotomous clinical outcomes were expressed as HRs and 
their 95% confidence intervals (CI). Our primary analyses used adjusted HRs per study. 
We evaluated statistical heterogeneity using the Cochran chi-square, the I
2
 statistic, and the 






 values of 30-60% represented a 
moderate level of heterogeneity. A p value <0.1 for the chi-square was defined as 
indicating the presence of heterogeneity; a Tau
2
>1 suggests the presence of substantial 
statistical heterogeneity. Publication bias was explored with the funnel plot and tested with 
the Egger test of funnel plot asymmetry.
23
 We performed pre-specified subgroup analyses 
of effects on T2DM patients only. A sensitivity analyses combining unadjusted HRs was 



















3.1. Study selection 
Our search identified 437 publications (Fig. 1). After removing duplicates, 290 articles 
were screened by study title/abstract for relevance to study topic and inclusion/exclusion 
criteria. Thirteen articles were retrieved for full-text analysis (Fig. 1). Six studies (n=4,704 
women with EC) reported overall mortality women with EC and were available for 
qualitative synthesis.
25-30
 Finally, 5 studies (n=4,239 women with EC) reported effects on 
overall mortality comparing metformin use and non-metformin use groups and were 
included in the quantitative synthesis.
25-29
 Other pre-specified outcomes (cancer-specific 
mortality, disease progression, and metastases) were not reported in evaluated studies. 
 
3.2. Characteristics of included studies 
Table 1 summarizes the main characteristics of the included studies. The 6 articles 
(n=4,723) included in the qualitative analysis were retrospective cohort studies. Four 
studies were conducted in the United States,
25,26,28,29
 one in Poland,
27
 and one in Austria.
30
 
Sample size in these studies ranged from 107 to 1,495 EC cases identified by clinical 
records. Four studies enrolled EC patients classified as International Federation of 
Obstetrics and Gynecology (FIGO) clinical stages I to IV,
25,26,28,30
 one study enrolled 
patients with FIGO clinical stages I to III,
27
 while the sixth study enrolled patients with 
FIGO clinical stages III-IV or recurrent EC.
29
 
 The mean age (standard deviation [SD]) ranged from 63.6 (4.1)
26
 and 64.6 
(11.5).
28
 Overall follow-up ranged from a median of 2.8 years
26
 to a mean of about 9.3 















 Mean body mass index (BMI) were >30 kg/m
2
in majority of the studies. EC 
patients treated with metformin ranged from 8.9% to 23.8% in the six cohorts (Table 1). 
 
3.3. Risk of bias assessment 
Using the Newcastle-Ottawa Scale (NOS), all 5 studies included in the meta-analysis were 
identified as having low risk of bias (Table 2). All but one study
27
 identified important 
confounders or prognostic factors and were used for adjustment of the association between 
metformin use and outcomes in EC. There was considerable variation in the selection of 
confounding variables for adjustment although four studies
25,26,28,29
 had at the least adjusted 
for age and cancer stage. 
 
3.4. Meta-analyses of overall mortality 
In four studies evaluating EC patients and with available adjusted effects (n=4,132), 
metformin use was associated with a significant reduction in overall mortality in 
comparison with not using metformin (adjusted HR [aHR] 0.64, 95%CI 0.45 to 0.89, 
p=0.009) (Fig. 2). In three studies only evaluating EC patients with T2DM and with 
available adjusted effects (n=2,637), metformin was also associated with a reduction in 
overall mortality (aHR 0.50, 95%CI 0.34 to 0.74, p=0.0006) (Fig. 3). There was low to 
moderate heterogeneity of adjusted effects across studies for all analyses. Unadjusted 
effects from 3 studies (n=1,441) were also meta-analyzed, but metformin was not 
associated with lower mortality vs not using metformin (unadjusted HR 0.82, 95%CI 0.61-
1.09, p=0.17) (Fig. 4). 
 
4. Discussion 













Our meta-analysis showed that metformin significantly reduced overall mortality in 
patients with EC in a wide range of FIGO clinical stages compared to those not treated with 
metformin. In addition, there was also a reduced overall mortality associated with 
metformin treatment when only EC patients with T2DM were evaluated. There was low to 
moderate heterogeneity of effects among evaluated studies. 
Previous studies and meta-analyses have demonstrated that long term exposure to 
metformin (but not sulfonylurea) reduces the risk of colorectal and non-small cell lung 
cancer in patients with T2DM.
31,32
 In contrast, metformin use did not have a significant 
effect on the incidence of endocrine-dependent cancers such as breast or prostate 
cancer.
8,33-35
 However, some of these observations have been limited by inadequate follow-
up of patients in these studies and lack of confirmation from randomized controlled 
trials.
36,37
 On the other hand, metformin use may substantially improve cancer survival, 
whilst insulin exposure is associated to increases in other-than-cancer mortality. For these 




EC risk factors including postmenopausal age, obesity, hypertension and impaired glucose 
tolerance, are associated with hyperinsulinemia and insulin resistance. Hence, circulating 
insulin and C-peptide levels and the HOMA-IR values are higher in women with EC.
4
 The 
relationship between insulin resistance, DM and EC seems to be causal as has been shown 
by Mendelian randomization studies.
39
 In vitro studies have demonstrated that metformin 
inhibits insulin action, reduces migration capacity of endometrial epithelial cells without 
reduction of proliferation, and the effect may be globally considered as an anti-metastatic 
effect in conditions of high as well as normal glucose levels.
40
 Metformin also induces 
apoptosis on endometrial cancer cells,
41
 and antidiabetic doses of metformin produces 













hypermethylation of tumor-promoting pathway genes and inhibition of cell proliferation in 
both normal and cancer cells.
42
 
In our systematic review and meta-analysis, available studies were heterogeneous with 
respect to studied populations which included EC patients in FIGO stages I to IV and 
recurrent cases. In general, one may consider that early stages of the disease (stages I and 
II) have high rates of curation with surgery and the mortality risk is very low and and thus 
can be challenging to detect a benefit for metformin treatment. The available studies did 
not allow to assess the effect of metformin according to clinical stages, duration of 
metformin of treatment, and years of evolution of T2DM. A second source of heterogeneity 
may be therapeutic approaches which may differ from one institution to another; in 
addition, clinical practice for management of the EC and guidelines include a wide variety 
of treatment options and follow-up recommendations in stages III, IV and recurrences.
43-45
 
Although only few observational studies have studied the relationship between metformin 
use and EC mortality, our meta-analysis findings demonstrate a clear association between 
them. 
EC is a prevalent disease among postmenopausal women and in those with either excessive 
weight or BMI > 30 kg/m
2
. Most of included studies in the current review reported an 
average BMI of more than 30 kg/m
2
 in patients with EC. This profile of women is also 
overlapping with those suffering with T2DM. Furthermore, in the current meta-analysis 
postmenopausal women with T2DM and EC had a larger mortality risk reduction with 
metformin in comparison to those diabetics without metformin. Further well-designed, 
large studies can vastly improve our understanding on how best to utilize metformin in the 
management of patients with EC. Future research should report information on duration of 
T2DM and metformin treatment and dosages, analyze patients by FIGO clinical stages and 
histological types (type I endometrioid EC versus type II non-endometrioid EC), provide 













details about surgical and other complementary treatments and have longer follow-up 
times. 
Our study has several limitations. First, the observational nature of cohort studies cannot 
exclude that the effect of metformin on mortality may be associated to other patient 
characteristics. Second, we expected substantial heterogeneity of study characteristics 
among studies such as EC stage, duration of metformin use, or metformin dose; to 
accommodate this methodological heterogeneity we used random effects models. Third, 
variability of effects across studies (i.e. statistical heterogeneity) was expected; however, 
we found a low to moderate heterogeneity of effects. Fourth, the number of studies was 
low, and we could not evaluate the probability of publication bias. Finally, the set of 
variables used to adjust effects was different among studies.  
In conclusion, this systematic review and meta-analysis demonstrated that metformin 
treatment reduced overall mortality in postmenopausal women with EC. Large 
observational studies are necessary to further elucidate the protective effects of metformin 




FRP-L and AVH designed the study. 
FRP-L and VP did the literature searches and designed the data-extraction form. 
FRP-L, XG, GP-A and WH-F extracted data. 
VP and FRP-L cross-checked the data extraction. 
VP did the statistical analyses. 
AVH supervised the statistical analyses. 
All authors wrote the paper, and read and approved the submitted version. 
 
 
Conflict of interest  













The authors declare that they have no conflict of interest. 
 
Funding 
There was no specific funding for this review. 
 
 
Provenance and peer review  
This article has undergone peer review. 
 
 













REFERENCES   
 [1] Felix AS, Yang HP, Bell DW, Sherman ME. Epidemiology of endometrial carcinoma: 
Etiologic importance of hormonal and metabolic influences. Adv Exp Med Biol 
2017;943:3-46. 
[2] Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial 
cancer: a meta-analysis. Diabetologia 2007;50:1365-74.  
[3] Brinton LA, Trabert B, Anderson GL, Falk RT, Felix AS, Fuhrman BJ, et al. Serum 
estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal 
women. Cancer Epidemiol Biomarkers Prev 2016;25:1081-9. 
[4] Hernandez AV, Pasupuleti V, Benites-Zapata VA, Thota P, Deshpande A, Perez-Lopez 
FR. Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis. 
Eur J Cancer 2015;51:2747-58. 
[5] Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and 
incidence of cancer: a systematic review and meta-analysis of prospective observational 
studies. Lancet 2008;371:569–78. 
[6] Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: 
epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009;114:121–7. 
[7] Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-
specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 
2012;35:1835-44. 
[8] Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and 
sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using 
primary data of published studies. Metabolism 2013;62:922-34. 
[9] Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and 
cancer: Umbrella review of metaanalyses of observational studies. BMJ 2015;350:g7607.  













[10] Arnold M, Jiang L, Stefanick ML, Johnson KC, Lane DS, LeBlanc ES, et al. Duration 
of adulthood overweight, obesity, and cancer risk in the Women's Health Initiative: A 
longitudinal study from the United States. PLoS Med 2016;13:e1002081. 
[11] Aarestrup J, Gamborg M, Tilling K, Ulrich LG, Sørensen TI, Baker JL. Childhood 
body mass index growth trajectories and endometrial cancer risk. Int J Cancer 
2017;140:310-5. 
[12] Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. 
Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. 
PLoS One2013;8:e71583. 
[13] Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer 
incidence and mortality: A meta-analysis. Cancer Epidemiology2013;37:207-18.  
[14] Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on 
endometrialcancer cell growth in vivo: a preoperative prospective trial. Cancer 
2014;120:2986-95. 
[15] Sivalingam VN, Kitson S, McVey R, Roberts C, Pemberton P, Gilmour K, et al. 
Measuring the biological effect ofpresurgical metformin treatment in endometrial cancer. 
Br J Cancer 2016;114:281-9. 
[16] Perez-Lopez FR. Metformin treatment and evolution of endometrial cancer. 
Climacteric 2014;17:207-9. 
[17] Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent 
diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014;16:707-10. 
[18] Wells GA, Shea,B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-
Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [21 December 2016] 













[19] Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting 
items for systematic reviews and metaanalyses: the PRISMA statement. J Clin Epidemiol 
2009;62:1006-12. 
[20] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 
1986;7:177-88. 
[21] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
analyses. BMJ 2003;327:557-60. 
[22] Higgins JP. Commentary: heterogeneity in meta-analysis should be expected and 
appropriately quantified. Int J Epidemiol2008;37:1158-60. 
[23] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a 
simple graphical test. BMJ 1997;315:629-34. 
[24] Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The 
Nordic Cochrane Centre, The Cochrane Collaboration; 2011. 
[25] Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al. Metformin is 
associated with improved survival in endometrial cancer. Gynecol Oncol 2014;132:438-42. 
[26] Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, et al. 
Metformin use and endometrial cancer survival. Gynecol Oncol 2014; 132:236-40. 
[27] Lemanska A, Zaborowski M, Spaczynski E, Nowak-Markwitz E. Do endometrial 
cancer patients benefit from metformin intake? Ginekologia Polska 2015;86:419-23. 
[28].  Al Hilli MM, Bakkum-Gamez JN, Mariani A, Cliby WA, Mc Gree ME, Weaver AL, 
et al. The effect of diabetes and metformin on clinical outcomes is negligible in risk-
adjusted endometrial cancer cohorts. Gynecol Oncol 2016;140:270-6.  
[29] Ezewuiro O, Grushko TA, Kocherginsky M, Habis M, Hurteau JA, Mills KA, et al. 
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated 
with Chemotherapy. PLoS One 2016;11:e0147145.  













[30] Seebacher V, Bergmeister B, Grimm C, Koelbl H, Reinthaller A, Polterauer S. The 
prognostic role of metformin in patients with endometrial cancer: a retrospective study. Eur 
J Obstet Gynecol Reprod Biol 2016;203:291-6.  
[31]. Mei ZB, Zhang ZJ, Liu CY, Liu Y, Cui A, Liang ZL, Wang GH, Cui L. Survival 
benefits of metformin for colorectal cancer patients with diabetes: a systematic review and 
meta-analysis. PLoS One 2014;9:e91818. 
[32] Arrieta O, Varela-Santoyo E, Soto-Perez-de-Celis E, Sánchez-Reyes R, De la Torre-
Vallejo M, Muñiz-Hernández S, et al. Metformin use and its effect on survival in diabetic 
patients with advanced non-small cell lung cancer. BMC Cancer 2016;16:633. 
[33] Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-
Duijvestijn PH, et al. Lower risk of cancer in patients on metformin in comparison with 
those on sulfonylurea derivatives: results from a large population-based follow-up study. 
Diabetes Care 2012;35:119-24. 
[34] Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk 
associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. 
Oncologist 2012;17:813-22. 
[35] Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg 
L, et al. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of 
prostate cancer. Int J Cancer 2017;140:611-7. 
[36] Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, et al. 
Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice 
Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 2014;37:2522-32. 
[37] Kowall B, Stang A, Rathmann W, Kostev K. No reduced risk of overall, colorectal, 
lung, breast, and prostate cancer with metformin therapy in diabetic patients: database 
analyses from Germany and the UK. Pharmacoepidemiol Drug Saf 2015;24:865-74. 













[38] Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, et al. Cancer mortality 
reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes 
Obes Metab 2012;14:23-9. 
[39] Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, et al. 
Evidence of a causal association between insulinemia and endometrial cancer: A mendelian 
randomization analysis. J Natl Cancer Inst 2015;107: pii: djv178. 
[40] de Barros Machado A, Dos Reis V, Weber S, Jauckus J, Brum IS, von Eye Corleta H, 
et al. Proliferation and metastatic potential of endometrial cancer cells in response to 
metformin treatment in a high versus normal glucose environment. Oncol Lett 
2016;12:3626-32. 
[41] Xie Y, Wang JL, Ji M, Yuan ZF, Peng Z, Zhang Y, et al. Regulation of insulin-like 
growth factor signaling by metformin in endometrial cancer cells.Oncol Lett 2014;8:1993-
1999. 
[42] Zhong T, Men Y, Lu L, Geng T, Zhou J, Mitsuhashi A, et al. Metformin alters DNA 
methylation genome-wide via the H19/SAHH axis. Oncogene. 2016 Oct 24. doi: 
10.1038/onc.2016.391. [Epub ahead of print] 
[43] SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J,  Leitao 
M, Salom E, Gehrig P, Olawaiye AB et al. for the Society of Gynecologic Oncology 
Clinical Practice Committee. Endometrial cancer: A review and current management 
strategies. Gynecologic Oncology 2014;134:385-92. 
[44] Colombo N,  Creutzberg C, Amant F,  Bosse T,  González-Martín A,  Ledermann J, et 
al; The ESMO–ESGO–ESTRO Endometrial Consensus Conference Working Group. 
ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment 
and follow-up. Radiotherapy Oncology 2015;117:559-81. 













[45] Fotopoulou C, Kraetschell R, Dowdy S, Fujiwara K, Yaegashi N, Larusso D, et al. 
Surgical and systemic management of endometrial cancer: An international survey. Arch 











































Figure 1: Flow chart of the study selection process for eligible studies 
 
Figure 2: Forest plot showing overall mortality risk (after adjustment) with metformin use 
in patients with endometrial cancer. 
 
Figure 3: Forest plot showing overall mortality risk (after adjustment) with metformin use 
in patients with endometrial cancer and diabetes mellitus. 
 
Figure 4: Forest plot showing overall mortality risk (before adjustment) with metformin use 
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available in 1,058: 
details NA 
8.9 64.6 (11.5) 
33.4 
(9.4) 
4.3 [2.7–6.9] years 
for diabetic 
patients, and 5.2 
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NOS; other types 
209 
















9.9 65.3* 29.0* 51 months  no no no no 
*median; EC = endometrial cancer; DM = diabetes mellitus; SD = standard deviation; HR = hazard ratio; NOS = not otherwise specified; NA = not available 
#34% of metformin users were also using sulfonylureas, 18% thiazolidinediones, 15% insulin, and 7% other anti-diabetic agents. Nearly one-third (29%) of non-metformin user diabetics used insulin based regimens. 












Table 2 Newcastle-Ottawa Scale for risk of bias assessment 
Selection criteria Comparability criteria Outcome criteria 
First author, year 
published 
Representativeness 
of the Exposed 
Cohort 






Outcome of Interest 
Was Not Present at 
Start of Study 
Comparability of Cohorts 





Long Enough for 









* * * * * (age) *( stage) * * * 9 
Ko EM, 2014  * * * * * (age) *( stage) * * * 9 
Lemanska A, 2014 * * * * - - * * * 7 
Al Hilli MM, 2016 * * * * * (age) *( stage) * * * 9 
Ezewuiro O, 2016 * * * * * (age) *( stage) * * * 9 
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